Selected research
Industry Research
Herpes Zoste Drug Industry Research Report 2026
Market perspective
The global Herpes Zoste Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Herpes Zoste Drug is forecast to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Herpes Zoste Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Herpes Zoste Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Herpes Zoste Drug include , among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Herpes Zoste Drug market in revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to Herpes Zoste Drug.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Herpes Zoste Drug Market by Company
Merck & Co., Inc.
Beijing Minhai Biotechnology Co., Ltd
Astellas Pharma Inc.
TSRL, Inc.
ReceptoPharm, Inc.
NAL Pharmaceuticals Ltd.
GlaxoSmithKline Plc
GeneOne Life Science, Inc.
Foamix Pharmaceuticals Ltd.
Epiphany Biosciences, Inc.
ContraVir Pharmaceuticals, Inc.
Herpes Zoste Drug Segment by Type
FV-100
GLS-5100
GSK-1437173A
NAL-3221
Amenamevir
Acyclovir
Others
Herpes Zoste Drug Segment by Application
Clinic
Hospital
Others
Herpes Zoste Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Herpes Zoste Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Herpes Zoste Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Herpes Zoste Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Herpes Zoste Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Herpes Zoste Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Herpes Zoste Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- FV-100
- GLS-5100
- GSK-1437173A
- NAL-3221
- Amenamevir
- Acyclovir
- Others
Applications
- Clinic
- Hospital
- Others
Companies covered
- Merck & Co., Inc.
- Beijing Minhai Biotechnology Co., Ltd
- Astellas Pharma Inc.
- TSRL, Inc.
- ReceptoPharm, Inc.
- NAL Pharmaceuticals Ltd.
- GlaxoSmithKline Plc
- GeneOne Life Science, Inc.
- Foamix Pharmaceuticals Ltd.
- Epiphany Biosciences, Inc.
- ContraVir Pharmaceuticals, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Herpes Zoste Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.2.2 FV-100
- 2.2.3 GLS-5100
- 2.2.4 GSK-1437173A
- 2.2.5 NAL-3221
- 2.2.6 Amenamevir
- 2.2.7 Acyclovir
- 2.2.8 Others
- 2.3 Herpes Zoste Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Clinic
- 2.3.3 Hospital
- 2.3.4 Others
- 2.4 Global Market Growth Prospects
- 2.4.1 Global Herpes Zoste Drug Production Value Estimates and Forecasts (2021-2032)
- 2.4.2 Global Herpes Zoste Drug Production Capacity Estimates and Forecasts (2021-2032)
- 2.4.3 Global Herpes Zoste Drug Production Estimates and Forecasts (2021-2032)
- 2.4.4 Global Herpes Zoste Drug Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Herpes Zoste Drug Production by Manufacturers (2021-2026)
- 3.2 Global Herpes Zoste Drug Production Value by Manufacturers (2021-2026)
- 3.3 Global Herpes Zoste Drug Average Price by Manufacturers (2021-2026)
- 3.4 Global Herpes Zoste Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Herpes Zoste Drug Key Manufacturers, Manufacturing Sites & Headquarters
- 3.6 Global Herpes Zoste Drug Manufacturers, Product Type & Application
- 3.7 Global Herpes Zoste Drug Manufacturers Established Date
- 3.8 Global Herpes Zoste Drug Market CR5 and HHI
- 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck & Co., Inc.
- 4.1.1 Merck & Co., Inc. Herpes Zoste Drug Company Information
- 4.1.2 Merck & Co., Inc. Herpes Zoste Drug Business Overview
- 4.1.3 Merck & Co., Inc. Herpes Zoste Drug Production, Value and Gross Margin (2021-2026)
- 4.1.4 Merck & Co., Inc. Product Portfolio
- 4.1.5 Merck & Co., Inc. Recent Developments
- 4.2 Beijing Minhai Biotechnology Co., Ltd
- 4.2.1 Beijing Minhai Biotechnology Co., Ltd Herpes Zoste Drug Company Information
- 4.2.2 Beijing Minhai Biotechnology Co., Ltd Herpes Zoste Drug Business Overview
- 4.2.3 Beijing Minhai Biotechnology Co., Ltd Herpes Zoste Drug Production, Value and Gross Margin (2021-2026)
- 4.2.4 Beijing Minhai Biotechnology Co., Ltd Product Portfolio
- 4.2.5 Beijing Minhai Biotechnology Co., Ltd Recent Developments
- 4.3 Astellas Pharma Inc.
- 4.3.1 Astellas Pharma Inc. Herpes Zoste Drug Company Information
- 4.3.2 Astellas Pharma Inc. Herpes Zoste Drug Business Overview
- 4.3.3 Astellas Pharma Inc. Herpes Zoste Drug Production, Value and Gross Margin (2021-2026)
- 4.3.4 Astellas Pharma Inc. Product Portfolio
- 4.3.5 Astellas Pharma Inc. Recent Developments
- 4.4 TSRL, Inc.
- 4.4.1 TSRL, Inc. Herpes Zoste Drug Company Information
- 4.4.2 TSRL, Inc. Herpes Zoste Drug Business Overview
- 4.4.3 TSRL, Inc. Herpes Zoste Drug Production, Value and Gross Margin (2021-2026)
- 4.4.4 TSRL, Inc. Product Portfolio
- 4.4.5 TSRL, Inc. Recent Developments
- 4.5 ReceptoPharm, Inc.
- 4.5.1 ReceptoPharm, Inc. Herpes Zoste Drug Company Information
- 4.5.2 ReceptoPharm, Inc. Herpes Zoste Drug Business Overview
- 4.5.3 ReceptoPharm, Inc. Herpes Zoste Drug Production, Value and Gross Margin (2021-2026)
- 4.5.4 ReceptoPharm, Inc. Product Portfolio
- 4.5.5 ReceptoPharm, Inc. Recent Developments
- 4.6 NAL Pharmaceuticals Ltd.
- 4.6.1 NAL Pharmaceuticals Ltd. Herpes Zoste Drug Company Information
- 4.6.2 NAL Pharmaceuticals Ltd. Herpes Zoste Drug Business Overview
- 4.6.3 NAL Pharmaceuticals Ltd. Herpes Zoste Drug Production, Value and Gross Margin (2021-2026)
- 4.6.4 NAL Pharmaceuticals Ltd. Product Portfolio
- 4.6.5 NAL Pharmaceuticals Ltd. Recent Developments
- 4.7 GlaxoSmithKline Plc
- 4.7.1 GlaxoSmithKline Plc Herpes Zoste Drug Company Information
- 4.7.2 GlaxoSmithKline Plc Herpes Zoste Drug Business Overview
- 4.7.3 GlaxoSmithKline Plc Herpes Zoste Drug Production, Value and Gross Margin (2021-2026)
- 4.7.4 GlaxoSmithKline Plc Product Portfolio
- 4.7.5 GlaxoSmithKline Plc Recent Developments
- 4.8 GeneOne Life Science, Inc.
- 4.8.1 GeneOne Life Science, Inc. Herpes Zoste Drug Company Information
- 4.8.2 GeneOne Life Science, Inc. Herpes Zoste Drug Business Overview
- 4.8.3 GeneOne Life Science, Inc. Herpes Zoste Drug Production, Value and Gross Margin (2021-2026)
- 4.8.4 GeneOne Life Science, Inc. Product Portfolio
- 4.8.5 GeneOne Life Science, Inc. Recent Developments
- 4.9 Foamix Pharmaceuticals Ltd.
- 4.9.1 Foamix Pharmaceuticals Ltd. Herpes Zoste Drug Company Information
- 4.9.2 Foamix Pharmaceuticals Ltd. Herpes Zoste Drug Business Overview
- 4.9.3 Foamix Pharmaceuticals Ltd. Herpes Zoste Drug Production, Value and Gross Margin (2021-2026)
- 4.9.4 Foamix Pharmaceuticals Ltd. Product Portfolio
- 4.9.5 Foamix Pharmaceuticals Ltd. Recent Developments
- 4.10 Epiphany Biosciences, Inc.
- 4.10.1 Epiphany Biosciences, Inc. Herpes Zoste Drug Company Information
- 4.10.2 Epiphany Biosciences, Inc. Herpes Zoste Drug Business Overview
- 4.10.3 Epiphany Biosciences, Inc. Herpes Zoste Drug Production, Value and Gross Margin (2021-2026)
- 4.10.4 Epiphany Biosciences, Inc. Product Portfolio
- 4.10.5 Epiphany Biosciences, Inc. Recent Developments
- 4.11 ContraVir Pharmaceuticals, Inc.
- 4.11.1 ContraVir Pharmaceuticals, Inc. Herpes Zoste Drug Company Information
- 4.11.2 ContraVir Pharmaceuticals, Inc. Herpes Zoste Drug Business Overview
- 4.11.3 ContraVir Pharmaceuticals, Inc. Herpes Zoste Drug Production, Value and Gross Margin (2021-2026)
- 4.11.4 ContraVir Pharmaceuticals, Inc. Product Portfolio
- 4.11.5 ContraVir Pharmaceuticals, Inc. Recent Developments
5 Global Herpes Zoste Drug Production by Region
- 5.1 Global Herpes Zoste Drug Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.2 Global Herpes Zoste Drug Production by Region: 2021-2032
- 5.2.1 Global Herpes Zoste Drug Production by Region: 2021-2026
- 5.2.2 Global Herpes Zoste Drug Production Forecast by Region (2027-2032)
- 5.3 Global Herpes Zoste Drug Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.4 Global Herpes Zoste Drug Production Value by Region: 2021-2032
- 5.4.1 Global Herpes Zoste Drug Production Value by Region: 2021-2026
- 5.4.2 Global Herpes Zoste Drug Production Value Forecast by Region (2027-2032)
- 5.5 Global Herpes Zoste Drug Market Price Analysis by Region (2021-2026)
- 5.6 Global Herpes Zoste Drug Production and Value, YOY Growth
- 5.6.1 North America Herpes Zoste Drug Production Value Estimates and Forecasts (2021-2032)
- 5.6.2 Europe Herpes Zoste Drug Production Value Estimates and Forecasts (2021-2032)
- 5.6.3 China Herpes Zoste Drug Production Value Estimates and Forecasts (2021-2032)
- 5.6.4 Japan Herpes Zoste Drug Production Value Estimates and Forecasts (2021-2032)
6 Global Herpes Zoste Drug Consumption by Region
- 6.1 Global Herpes Zoste Drug Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 6.2 Global Herpes Zoste Drug Consumption by Region (2021-2032)
- 6.2.1 Global Herpes Zoste Drug Consumption by Region: 2021-2026
- 6.2.2 Global Herpes Zoste Drug Forecasted Consumption by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Herpes Zoste Drug Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Herpes Zoste Drug Consumption by Country (2021-2032)
- 6.3.3 United States
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Herpes Zoste Drug Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Herpes Zoste Drug Consumption by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Russia
- 6.4.8 Spain
- 6.4.9 Netherlands
- 6.4.10 Switzerland
- 6.4.11 Sweden
- 6.4.12 Poland
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Herpes Zoste Drug Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Herpes Zoste Drug Consumption by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 India
- 6.5.7 Australia
- 6.5.8 Taiwan
- 6.5.9 Southeast Asia
- 6.6 South America, Middle East & Africa
- 6.6.1 South America, Middle East & Africa Herpes Zoste Drug Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East & Africa Herpes Zoste Drug Consumption by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 Argentina
- 6.6.5 Chile
- 6.6.6 Turkey
- 6.6.7 GCC Countries
7 Segment by Type
- 7.1 Global Herpes Zoste Drug Production by Type (2021-2032)
- 7.1.1 Global Herpes Zoste Drug Production by Type (2021-2032) & (W Units)
- 7.1.2 Global Herpes Zoste Drug Production Market Share by Type (2021-2032)
- 7.2 Global Herpes Zoste Drug Production Value by Type (2021-2032)
- 7.2.1 Global Herpes Zoste Drug Production Value by Type (2021-2032) & (US$ Million)
- 7.2.2 Global Herpes Zoste Drug Production Value Market Share by Type (2021-2032)
- 7.3 Global Herpes Zoste Drug Price by Type (2021-2032)
8 Segment by Application
- 8.1 Global Herpes Zoste Drug Production by Application (2021-2032)
- 8.1.1 Global Herpes Zoste Drug Production by Application (2021-2032) & (W Units)
- 8.1.2 Global Herpes Zoste Drug Production Market Share by Application (2021-2032)
- 8.2 Global Herpes Zoste Drug Production Value by Application (2021-2032)
- 8.2.1 Global Herpes Zoste Drug Production Value by Application (2021-2032) & (US$ Million)
- 8.2.2 Global Herpes Zoste Drug Production Value Market Share by Application (2021-2032)
- 8.3 Global Herpes Zoste Drug Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
- 9.1 Herpes Zoste Drug Value Chain Analysis
- 9.1.1 Herpes Zoste Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Herpes Zoste Drug Production Mode & Process
- 9.2 Herpes Zoste Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Herpes Zoste Drug Distributors
- 9.2.3 Herpes Zoste Drug Customers
10 Global Herpes Zoste Drug Analyzing Market Dynamics
- 10.1 Herpes Zoste Drug Industry Trends
- 10.2 Herpes Zoste Drug Industry Drivers
- 10.3 Herpes Zoste Drug Industry Opportunities and Challenges
- 10.4 Herpes Zoste Drug Industry Restraints
11 Report Conclusion
12 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst